ArticleIndian journal of gastroenterology : official journal of the Indian Society of Gastroenterology2017
Risk factors for non-alcoholic fatty liver disease are common in patients with non-B non-C hepatocellular carcinoma in India.
Article in Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 22 citations in OpenAlex.
- Nanomedicine Strategies Utilizing Lipid-Based Nanoparticles for Liver Cancer Therapy: Exploring Signaling Pathways and Therapeutic Modalities.Advanced pharmaceutical bulletin · 2024Review
- Etiologic fractions in patients of hepatocellular carcinoma in India with and without a background of cirrhosis: a multi-centric study.Hepatology international · 2023Article
- The changing epidemiology of hepatocellular carcinoma!Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2023Article
- Multi-center prospective survey of hepatocellular carcinoma in Kerala: More than 1,200 cases.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2023Article
- Profile of patients with hepatocellular carcinoma: An experience from a tertiary care center in India.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2022Observational
- MAFLD enhances clinical practice for liver disease in the Asia-Pacific region.Clinical and molecular hepatology · 2022Review
- First-line sorafenib sequential therapy and liver disease etiology for unresectable hepatocellular carcinoma using inverse probability weighting: A multicenter retrospective study.Cancer medicine · 2021Article
- Comparison of clinical and metabolic profiles of lean versus non-lean nonalcoholic fatty liver disease.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2021Article
- ACTG1 and TLR3 are biomarkers for alcohol-associated hepatocellular carcinoma.Oncology letters · 2019Article
- Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: An increasing concern.The Indian journal of medical research · 2019Review
- Staging systems of hepatocellular carcinoma: A review.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2018Review
- Prevalence of Risk Factors for Nonalcoholic Fatty Liver Disease in Middle-Aged and Elderly Patients With Cryptogenic Cirrhosis.Journal of clinical and experimental hepatologyArticle
- Indian National Association for Study of the Liver (INASL) Guidance Paper on Nomenclature, Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease (NAFLD).Journal of clinical and experimental hepatologyReview
- What Are the Current Pharmacological Therapies for Nonalcoholic Fatty Liver Disease?Journal of clinical and experimental hepatologyReview
- 2019 Update of Indian National Association for Study of the Liver Consensus on Prevention, Diagnosis, and Management of Hepatocellular Carcinoma in India: The Puri II Recommendations.Journal of clinical and experimental hepatologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aim of the studyThe aim of the study was to analyze the prevalence of risk factors for non-alcoholic fatty liver disease (NAFLD) in patients with non-B non-C hepatocellular carcinoma (HCC).
methodsBetween June 2012 and November 2014, patients with HCC, negative for hepatitis B surface antigen and hepatitis C virus antibody, were included in this study. All patients were assessed for risk factors for NAFLD such as diabetes mellitus (DM), hypertension, dyslipidemia, metabolic syndrome, and obesity.
resultsForty-seven patients with non-B non-C HCC (males, 37; age, 60±10 years; mean±SD) were studied. Model for end-stage liver disease score was 11±4. Twenty-five patients were in Child's class A. History of significant alcohol intake was noted in 11 (23%) patients. Prevalence of risk factors for NAFLD were obesity 24 (51%), DM 22 (47%), metabolic syndrome 21 (45%), hypertension 16 (34%), and dyslipidemia 13 (28%). Forty (85%) patients had at least one risk factor for NAFLD. The mean duration of at least one NAFLD risk factor was 7.5 years, prior to diagnosis of HCC. Thirteen (28%) patients were positive for anti-HBc; however, none of the study patients had detectable HBV DNA in blood.
conclusionsEighty-five percent of the patients with non-B non-C HCC had at least one risk factor for NAFLD. None of the study patients had occult hepatitis B infection. NAFLD is emerging as the major etiological contributing factor for non-B non-C HCC in India.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.